Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 1
2014 2
2017 3
2018 3
2019 1
2020 1
2022 3
2023 4
2024 7
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA, Graf RP, Kalinsky K. Bhave MA, et al. Breast Cancer Res Treat. 2024 Oct;207(3):599-609. doi: 10.1007/s10549-024-07376-w. Epub 2024 Jun 14. Breast Cancer Res Treat. 2024. PMID: 38872062 Free PMC article.
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Pierga JY, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M. Jhaveri KL, et al. Among authors: bhave m. J Clin Oncol. 2024 Dec 10;42(35):4173-4186. doi: 10.1200/JCO.23.02733. Epub 2024 Sep 6. J Clin Oncol. 2024. PMID: 39241211 Free PMC article. Clinical Trial.
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y, Banerjee A, Xie P, Ivanov AA, Uddin A, Jiao Q, Chi JJ, Zeng L, Lee JY, Xue Y, Lu X, Cristofanilli M, Gradishar WJ, Henry CJ, Gillespie TW, Bhave MA, Kalinsky K, Fu H, Bahar I, Zhang B, Wan Y. Zhu Y, et al. Among authors: bhave ma. J Clin Invest. 2024 Mar 26;134(10):e176390. doi: 10.1172/JCI176390. J Clin Invest. 2024. PMID: 38530357 Free PMC article.
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Kalinsky K, Spring L, Yam C, Bhave MA, Ntalla I, Lai C, Sjekloca N, Stwalley B, Stokes M, Taylor A, Nanda R. Kalinsky K, et al. Among authors: bhave ma. Breast Cancer Res Treat. 2024 Nov;208(1):203-214. doi: 10.1007/s10549-024-07412-9. Epub 2024 Jun 21. Breast Cancer Res Treat. 2024. PMID: 38904892 Free PMC article.
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.
Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, Carter S, Bidard FC, Fasching PA, Aftimos P, Wheatley D, Hamilton E, Aft R, Kulkarni S, Schmid P, Bhave M, Ismail-Khan R, Karacsonyi C, Estrem ST, Nguyen B, Ozbek U, Yuen E, Rodrik-Outmezguine V, Ciruelos E. Neven P, et al. Among authors: bhave m. Clin Cancer Res. 2024 Dec 2;30(23):5304-5313. doi: 10.1158/1078-0432.CCR-24-2113. Clin Cancer Res. 2024. PMID: 39377773 Free PMC article. Clinical Trial.
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.
Jhaveri K, Anders CK, Bardia A, Bhave M, Chien AJ, Krop I, Traina TA, Abdou Y, Basho R, Conlin AK, Esteva FJ, Fox KR, Gadi V, Kaufman PA, Litvak A, Ma CX, Mamounas EP, McArthur H, McCann K, Mitri Z, Shatsky R, Telli M, Torres MA, Kalinsky K. Jhaveri K, et al. Among authors: bhave m. Clin Breast Cancer. 2025 Aug;25(6):e699-e706. doi: 10.1016/j.clbc.2025.04.007. Epub 2025 Apr 8. Clin Breast Cancer. 2025. PMID: 40340127
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
Bhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M. Bhave M, et al. Breast Cancer Res. 2025 Dec 21;28(1):18. doi: 10.1186/s13058-025-02168-6. Breast Cancer Res. 2025. PMID: 41423595 Free PMC article.
28 results